Effect of trastuzumab combined with ECT chemotherapy regimen on efficacy,serum CA153,CEA and hematopoietic function in patients with advanced breast cancer
Objective To investigate the impact of trastuzumab combined with epirubicin (E), cyclophosphamide(C)and taxol(T)chemotherapy on therapeutic effects,serum carbohydrate antigen 153 (CA153),carcinoembryonic antigen(CEA)and hematopoietic function in patients with advanced breast can-cer. Methods A total of 60 patients with advanced breast cancer who were admitted to Funan County People's Hospital in Anhui Province from October 2019 to October 2022 were selected. They were divided into two groups:the ECT group (30 patients receiving ECT chemotherapy) and the combination group (30 patients treated with trastuzumab in addition to ECT chemotherapy),based on a random number table. Clinical effica-cy,serum levels of CA153 and CEA,hematopoietic function,and adverse reactions were compared between the two groups. Results The effective rate in the combination group was higher than that in the ECT group (96.67％vs. 80.00％),with a statistically significant difference(c2=4.043,P<0.05). After treatment,serum CA153 and CEA levels in both groups decreased. By the end of the treatment course ,serum CA153 and CEA levels in the combination group were lower than those in the ECT group ,with statistically significant differenc-es (t=14.795,17.472,P<0.05). Platelet count (PLT),hemoglobin (Hb),and white blood cell count (WBC)decreased in both groups after treatment. At the end of the treatment course ,there were no statistically significant differences in the above indicators or the incidence of adverse reactions between the two groups(t=1.052,1.751,1.676,P>0.05). Conclusion Compared to using ECT chemotherapy alone,combining ECT chemotherapy with trastuzumab can enhance the clinical outcomes for patients with advanced breast cancer. This combination treatment also lowers serum CA153 and CEA levels without impacting hematopoietic and im-mune functions.
Breast cancerAdvanced stageTrastuzumabECT chemotherapyCarbohydrate antigen 153Carcinoembryonic antigen
万方数据
维普
